MIL-OSI Europe: Written question – Combating vector-borne diseases as part of the review of the Biocidal Products Regulation – E-002614/2025

Question for written answer  E-002614/2025
to the Commission
Rule 144
Benoit Cassart (Renew), Olivier Chastel (Renew)

Since Regulation (EU) No 528/2012 concerning the making available on the market and use of biocidal products entered into force, Article 72 thereof has forbidden any advertisement of the characteristics of such products, even when these are based on proven evidence (effectiveness, safety, chemical properties and manufacturing process). This ban prevents manufacturers of approved skin-applied repellents from providing information aimed at vulnerable groups (pregnant women, infants and immunocompromised patients) even though the people concerned cannot be vaccinated against vector-borne diseases like dengue fever and chikungunya. This is at odds with public health objectives and citizens’ right to information.

• 1.Does the Commission plan to include a targeted exemption from Article 72 for biocides meant for use by certain vulnerable groups, in order to allow for justified, clear and responsible communication?
• 2.As part of the ongoing review, what measures does the Commission plan to propose to guarantee access to vital information and to make sure that products that protect vulnerable groups are available on the market?

Submitted: 28.6.2025